Zentalis Pharmaceuticals (ZNTL) Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at AACR
- World stocks edge back, bond yields, COVID-19 cases rise
- IBM (IBM) Tops Q1 EPS by 14c, Revenue Beats
- Tesla's (TSLA) Musk says data logs from crashed vehicle show Autopilot was not enabled, car did not purchase FSD
- Dollar falls to lowest in more than seven weeks
- Bitcoin (BTC) Price Fell 20% Off the Highs Over the Weekend as Markets Got 'Too Excited' About Coinbase (COIN), Says Mike Novogratz
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that three abstracts have been accepted for presentation, including a late-breaker on its WEE1 inhibitor, ZN-c3, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021. The meeting will be held virtually on April 10-15 and May 17-21, 2021.
“The important data we are presenting at AACR supports the ability of our Integrated Discovery Engine to develop differentiated oncology therapeutic candidates across diverse cancer targets and types,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis Pharmaceuticals. “We especially look forward to presenting clinical data from our ongoing Phase 1 monotherapy trial of our WEE1 inhibitor, ZN-c3, selected for a late-breaking session. In addition, results from two cell-based studies of ZN-c3, and our EGFR inhibitor, ZN-e4, demonstrated impressive selectivity and tolerability, which we believe positions these candidates to improve upon the constraints of existing products.”
Late-Breaker Oral Presentation:
Title: Clinical activity of a single-agent ZN-c3, an oral WEE1 inhibitor, in a Phase 1 dose-escalation trial in patients with advanced solid tumors Session: Early Clinical Trials with New Anticancer Agents Presentation Number: CT016 Date/Time: Saturday, April 10, 2021 at 1:30 p.m. EDT
Title: Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile Session: Molecular and Cellular Biology / GeneticsAbstract ID: 1965Date/Time: Available starting on Saturday, April 10, 2021 at 8:30 a.m. EDT
Title: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer Session: Oncogene Growth Factors and their ReceptorsAbstract ID: 2423Date/Time: Available starting on Saturday, April 10, 2021 at 8:30 a.m. EDT
The poster presentation abstracts are currently available on the AACR Annual Meeting 2021 website at www.aacr.org/meeting/aacr-annual-meeting-2021/.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) Granted FDA Breakthrough Therapy Designation for Bemarituzumab
- PayPal (PYPL) to Launch a Local Wallet in China to Facilitate Cross-Border Payments
- UPDATE: Sandvik (SAND) Reports Q1 EPS of $2.13
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!